Abstract
0.7, pZ 0.01).Within the BRAF-mutated subgroup, therewas no difference in tumor LC based on exposure to a BRAF inhibitor. There was also a trend towards improved CNS progression free survival (PFS) at 1 year (26% vs. 0%, pZ0.06), favoring BRAF-mutated patients. There was no difference in overall survival between the groups. Conclusion: In this retrospective study we found that BRAF mutation was associated with an improvement in local control for melanoma brain metastases treated with SRS compared to those without the mutation. There was also a trend for improved CNS PFS. Our data suggest that BRAF mutation may sensitize tumors to radiosurgery, and that BRAF wild-type tumors may be more radioresistant. Additional studies will be required to fully characterize the role of BRAF mutation in LC of brain metastases treated with SRS. Author Disclosure: I.S. Gallaher: None. Y. Watanabe: None. K.E. Dusenbery: None. C.K. Lee: None. H. Lin: None. T.E. DeFor: None. J. Yuan: None.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
